Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cullinan Therapeutics

7.76
+0.01000.13%
Volume:1.44M
Turnover:11.22M
Market Cap:457.95M
PE:-2.51
High:7.98
Open:7.75
Low:7.63
Close:7.75
Loading ...

Cullinan Therapeutics Receives Approval From European Medicines Agency to Initiate Phase 1 Trial of Cln-978, a Bispecific Cd19 T Cell Engager Administered Subcutaneously, in Patients With Rheumatoid Arthritis

THOMSON REUTERS
·
16 Apr

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

GlobeNewswire
·
16 Apr

Cullinan Oncology Coverage Assumed by Morgan Stanley at Overweight

Dow Jones
·
08 Mar

Cullinan Therapeutics: Promising Pipeline and Upcoming Catalysts Justify Buy Rating

TIPRANKS
·
07 Mar

Cullinan Oncology Price Target Maintained With a $33.00/Share by HC Wainwright & Co.

Dow Jones
·
28 Feb

Cullinan Management Faces Uncertainty Amid Market Forecast Challenges and Competitive Pressures

TIPRANKS
·
28 Feb

Cullinan Therapeutics Reports 2024 Financial Results and Updates

TIPRANKS
·
28 Feb

Cullinan Management Executives Cash In on Stock Sales

TIPRANKS
·
28 Feb

Analysts Are Bullish on Top Healthcare Stocks: GH Research (GHRS), Cullinan Management (CGEM)

TIPRANKS
·
28 Feb

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intellia Therapeutics (NTLA) and Cullinan Management (CGEM)

TIPRANKS
·
28 Feb

Cullinan Therapeutics Q4 2024 GAAP EPS $(0.73) Beats $(0.76) Estimate

Benzinga
·
27 Feb

BRIEF-Cullinan Oncology Q4 Pretax Profit USD -47.53 Million

Reuters
·
27 Feb

Cullinan Oncology Q4 Operating Expenses USD 55.048 Million

THOMSON REUTERS
·
27 Feb

Cullinan Therapeutics Inc: Qtrly Loss per Share $0.73

THOMSON REUTERS
·
27 Feb

Cullinan Therapeutics: Cash and Investments of $606.9 Mln as of Dec 31, 2024, Continues to Provide Runway Into 2028

THOMSON REUTERS
·
27 Feb

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

GlobeNewswire
·
27 Feb

Cullinan Therapeutics (NASDAQ:CGEM) Is In A Good Position To Deliver On Growth Plans

Simply Wall St.
·
31 Jan

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire
·
30 Jan

Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference

GlobeNewswire
·
30 Jan

Positive Phase 2b Trial Results Drive Price Target Revision and Future Growth Prospects for NSCLC Treatment

TIPRANKS
·
30 Jan